KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Long-Term Investments (2019 - 2025)

Adaptive Biotechnologies' Long-Term Investments history spans 6 years, with the latest figure at $13.2 million for Q4 2025.

  • For Q4 2025, Long-Term Investments fell 60.68% year-over-year to $13.2 million; the TTM value through Dec 2025 reached $13.2 million, down 60.68%, while the annual FY2025 figure was $13.2 million, 60.68% down from the prior year.
  • Long-Term Investments for Q4 2025 was $13.2 million at Adaptive Biotechnologies, up from $4.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $217.4 million in Q3 2021 and bottomed at $4.0 million in Q3 2025.
  • The 4-year median for Long-Term Investments is $33.7 million (2024), against an average of $70.6 million.
  • The largest annual shift saw Long-Term Investments surged 1220.17% in 2021 before it tumbled 90.94% in 2022.
  • A 4-year view of Long-Term Investments shows it stood at $217.1 million in 2021, then plummeted by 90.93% to $19.7 million in 2022, then soared by 70.88% to $33.7 million in 2024, then crashed by 60.68% to $13.2 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Long-Term Investments are $13.2 million (Q4 2025), $4.0 million (Q3 2025), and $24.1 million (Q2 2025).